<DOC>
	<DOCNO>NCT00002015</DOCNO>
	<brief_summary>To evaluate pharmacokinetics intravenous ganciclovir child ( age 3 month - 12 year ) . To determine safety tolerance 2 3 week induction course ganciclovir IV immunocompromised child receive treatment life- sight-threatening cytomegalovirus infection .</brief_summary>
	<brief_title>An Open Label Evaluation Safety Pharmacokinetics Ganciclovir Children</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Topical acyclovir . Consult Syntex study monitor follow : Cytokines . Soluble CD4 . Trichosanthin ( Compound Q ) . Imipenemcilastatin . Other investigational drug . Patients must follow : Congenital acquire immune deficiency . Eligibility receive ganciclovir treatment life sightthreatening Cytomegalovirus ( CMV ) disease . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Mild moderate Cytomegalovirus infection satisfy clinical severity criterion . Congenital neonatal CMV infection without documented congenital acquire immunodeficiency . Concurrent Medication : Excluded : Other myelosuppressive drug . Antimetabolites . Alkylating agent . Nucleoside analog ( topical acyclovir allow ) . Interferons . Foscarnet . Consult Syntex study monitor follow : Cytokines . Soluble CD4 . Trichosanthin ( Compound Q ) . Imipenemcilastatin . Other investigational drug . Patients follow exclude : Mild moderate Cytomegalovirus ( CMV ) infection meet clinical severity criterion . Absolute neutrophil count ( ANC ) &lt; 500 cells/mm3 platelet count &lt; 25000 platelets/mm3 . Note : Exceptions may make patient preexist neutropenia thrombocytopenia immediately lifethreatening disease , investigator believe delay start ganciclovir therapy advisable . In patient , investigator advise parent guardian risk bone marrow suppression increase risk infection bleed . Receiving exclude medication possible discontinue . Congenital neonatal CMV infection without documented congenital acquire immunodeficiency . Demonstrated hypersensitivity acyclovir ganciclovir .</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Immunocompromised Host</keyword>
</DOC>